Conclusion. Ceftobiprole is a novel, broad-spectrum, parenteral cephalosporin undergoing Phase III clinical trials. Its broad spectrum of activity makes it a candidate for monotherapy of cSSSIs ...
Japanese drug major Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), ...
Ceftobiprole has the potential to be used as monotherapy for the treatment of pneumonia and cSSSIs. Patients with DFIs and osteomyelitis were excluded from the cSSSI clinical trials, and ...
Years of growing resistance to antibiotics have sparked an urgent global health crisis, giving rise to challenging biological threats and the emergence of more dangerous ...
According to medical professionals, vitamin K reduces the blood-thinning effect of anticoagulants (such as Warfarin). When taken with cephalosporin antibiotics, the body's ability to absorb vitamin K ...
diff infection with 797,000 healthy controls. Study findings suggest that using clindamycin and later-generation cephalosporin antibiotics pose the greatest risk for C. diff infection. Meanwhile, the ...
They are commonly carbapenem- and/or 3rd generation cephalosporin-resistant (3GCR), which are drugs commonly used for serious infections. Our consortium's vision is to build a holistic picture of the ...
Anthrax: a minimum of 5million Units/day in divided doses until cure is effected. Cephalosporin, imipenem, or other allergy: not recommended. Asthma. Electrolyte imbalance possible with rapid IV ...